Absci vs Dare Bioscience
Absci is the larger business, with $2.8m of revenue in fiscal 2025 against $1.0m for Dare Bioscience (2.7 times as much). Dare Bioscience grew faster (10429.4% against -38.2%). Dare Bioscience kept more of each dollar of sales as profit: a net margin of -1300.7% against -4113.7%. Dare Bioscience carries less debt relative to equity (0.0% against 0.5%).
| Latest fiscal year | AbsciABSI, 2025 | Dare BioscienceDARE, 2025 |
|---|---|---|
| Revenue | $2.8m | $1.0m |
| Revenue growth | -38.2% | 10429.4% |
| Net income | −$115m | −$13.4m |
| Operating margin | -4297.0% | -1315.5% |
| Net margin | -4113.7% | -1300.7% |
| Return on equity | -62.5% | — |
| Free cash flow | −$94.0m | −$10.3m |
| Cash | $20.0m | $24.7m |
| Total debt | $873,000 | $0 |
| Debt to equity | 0.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 140 | 24 |
| Market value | $1.57bn | $9.7m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 5 buys, 2 sales | 0 buys, 0 sales |